ORIGINAL ARTICLE: CLINICAL

New recurrent chromosome change in pediatric therapy-related myelodysplastic syndrome: unbalanced translocation 1/6 with cryptic duplication of short arm of chromosome 6

Elisa Tassano¹, Elisa Tavella¹, Roberto Valli², Concetta Micalizzi³, Cristina Cuoco¹, Emanuela Maserati², Francesco Pasquali² & Cristina Morerio¹

¹Cancer Cytogenetic Laboratory and ³Department of Pediatric Hematology Oncology, Giannina Gaslini Institute, Genova, Italy and ²Department of Experimental and Clinical Biomedical Sciences, University of Insubria, Varese, Italy

Introduction

Therapy-related myelodysplastic syndrome (t-MDS) is a serious complication of cancer treatment. The incidence of pediatric t-MDS is between 7 and 18% of all childhood MDS, and this incidence has increased in recent years as a result of the increasing number of patients who survive their primary cancer [1]. The outcome of t-MDS is poor; hematopoietic stem-cell transplantation (HSCT) has improved the survival rate, but t-MDS is still associated with a significantly increased relapse risk compared to de novo MDS (33.3% vs. 70% 5-year relapse-free survival) [2]. MDS is uncommon in children and t-MDS represents only a fraction of patients with MDS, and thus limited and heterogeneous information on the clinical and cytogenetic characteristics is available. Most pediatric patients with t-MDS show an abnormal karyotype in the bone marrow (BM), and loss of chromosome 7 or deletion of chromosome 7 long arm are the most common abnormalities [3]. Unbalanced rearrangements involving the long arm of chromosome 1, with 1q trisomy, as well as structural changes of the short arm of chromosome 6, have been reported as recurrent in MDS, in particular in t-MDS [4,5], whereas an unbalanced translocation between chromosomes 1 and 6 with the presence of a derivative chromosome der(6)t(1;6)(q21∼23;p21.3) has been specifically associated with other myeloid disorders, in particular primary myelofibrosis [6]. In t-MDS and therapy-related acute myeloid leukemia (t-AML), a genomic gain of 5–6 Mb at 6p21 has been suggested as a new cryptic molecular rearrangement [7].

We report here two pediatric cases of t-MDS associated with the unbalanced translocation der(6)t(1;6)(q21∼23;q21;p21), in whom also a cryptic duplication at 6p11.2-p22.2 was found.

Patients and methods

Patient 1

The first patient is male, diagnosed with neuroblastoma stage IVS with MYCN amplification at 1 month of age in June 2005. Chemotherapy included four cycles of carboplatin/VP16, cyclophosphamide for hematopoietic stem cell mobilization, and busulfan/melphalan prior to autologous HSCT, performed when the child was 5 months old. A few months after the end of chemotherapy, when he was 1 year old, he developed an anaplastic large-cell lymphoma (ALCL) lympho-histiocytic type (NPM/ALK chimeric transcript positive on reverse transcription-polymerase chain reaction [RT-PCR]) and was treated according to the ALCL99 protocol,
i.e. with four cycles of ifosfamide, methotrexate, dexamethasone, VP16 and cytarabine at modulated doses due to his previous chemotherapy treatment, plus 4 months of maintenance with weekly vinblastine. One month after therapy discontinuation (December 2006) he developed cutaneous relapse of the lymphoma with molecular positive BM chimeric transcript, and therefore he was treated with cis-retinoic acid for 14 months. All treatments were completed when the patient was 2 years and 10 months old. When aged 3 years (May 2008), 1 month after cis-retinoic acid discontinuation, he presented moderate thrombocytopenia with increased mean platelet volume (MPV) (mean platelet count $80 \times 10^9$ cells/L, MPV 9.9 fL). By the age of 5 years (July 2010), he had monocytosis with the presence of immature myeloid cells in peripheral blood (PB) (white blood cells [WBC] $11 \times 10^9$/L, hemoglobin [Hb] 11.9 g/dL, platelets $76 \times 10^9$/L) and increased fetal hemoglobin (HbF; 6%). The differential blood count showed 70% neutrophils, 16% lymphocytes, 13% monocytes and 1% myelocytes. BM aspirate showed myeloid hyperplasia with dysmyelopoiesis, an increase in monocytes, and megakaryocytes with dysmorphic features (Figure 1). Tests for diagnosis of juvenile myelomonocytic leukemia were negative. NRAS, KRAS and PTPN11 oncogene mutations were not found, and there was no spontaneous proliferation of BM and PB mononuclear cells in vitro. The final clinical and hematological picture was compatible with a diagnosis of therapy-related chronic myelomonocytic leukemia (t-CMML). Currently, at the age of 7 years, the patient has clinical stability with mild splenomegaly without therapy.

**Patient 2**

Preliminary data on the second patient have already been reported by Morerio et al. [4]. A 7-month-old boy was diagnosed with medulloblastoma and treated according to the UK Children’s Cancer Study Group (UKCCSG) CNS 9204 protocol. After surgical resection, chemotherapy (carboplatin, etoposide, cyclophosphamide, vincristine, thiopeta, methotrexate) and radiotherapy (7.2 Gy $^{60}$Co, posterior fossa) were administered for 14 months. In January 2002, at 11 years of age, he was referred to us with a history of cold abscesses that responded only to steroids. We hypothesized a diagnosis of “streaking leukocyte syndrome,” or PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum and acne). He had a normal white blood cell count (WBC $5.1 \times 10^9$/L), mild anemia (Hb 9.7 g/dL, MCV 80 fL) and thrombocytopenia (platelet count $132 \times 10^9$/L). The differential blood count showed 11% neutrophils, 85% lymphocytes and 3% monocytes. The BM was hyperplastic with trilinear myelodysplastic features, numerous abnormal megakaryocytes, hyperplastic and vacuolated myeloid series with partial deficit of myeloperoxidase, and prominent dyserythropoiesis (Figure 2). MDS was classified as refractory cytopenia with multilineage dysplasia. This diagnosis was...
made 9 years after the end of chemotherapy. Allogeneic BM transplantation from a partially matched unrelated donor failed, and the patient died with disseminated aspergillosis.

**Cytogenetics**

Chromosome analyses were performed on unstimulated BM and PB cultures from the two patients by QFQ-banding technique. Fluorescence in situ hybridization (FISH) was carried out according to manufacturers’ protocols using a library for whole chromosome painting (wcp) and alphoid probes centromere-specific for chromosomes 1 and 6 in both patients.

**Array-CGH**

Comparative genomic hybridization on microarray (a-CGH) using a 180K genome-wide system (Agilent Technologies Inc., Santa Clara, CA) with an average resolution of 12–13 kb was performed according to the manufacturer’s instructions on DNA from BM sampled in February 2007 in patient 1, when he had normal hematological values and was on cis-retinoic acid treatment, and on DNA from BM of patient 2 sampled in September 2002, 9 months after the development of PAPA syndrome.

DNA was extracted using a Qiagen Blood and Tissue Kit (Qiagen GmbH, Hilden, Germany), and competitor DNA was purchased from Promega (Promega Corporation, Madison, WI). Slides were scanned using an Agilent microarray scanner G2565CA, and microarray images were analyzed using Agilent Feature Extraction 10.7.3.1 and Genomic Workbench 5.0.14 software. All a-CGH results refer to the genomic map Hg19.

**Results**

**Patient 1**

Chromosome analysis carried out on BM at ALCL onset showed a normal karyotype in 16 mitoses analyzed. At the time of cutaneous relapse in December 2006, 19 out of 35 metaphases examined showed an unbalanced translocation between chromosomes 1 and 6, confirmed by wcp, resulting in partial trisomy 1 and partial monosomy 6, and the karyotype was interpreted as follows: 46,XY,der(6)t(1;6)(q21;p22)/46,XY (Figure 3). This abnormal clone was found again at six different chromosome analyses performed in 2007–2008, always in the majority of mitoses analyzed.
the same period, the NPM/ALK rearrangement gradually disappeared at molecular analysis. Then, in December 2008 and September 2010, all mitoses analyzed on NPM/ALK-negative BM showed the unbalanced translocation (27 and 20 mitoses, respectively).

The imbalances of the abnormal clone were characterized by a-CGH, which showed a gain of material of the long arm of chromosome 1, from band q21.1 to qter (104.2 Mb, 145 076 147–249 212 609 bp), and a loss of chromosome 6 short arm from pter to band p22.2 (26.6 Mb, 170 426–26 663 345 bp), but also duplication of a segment of chromosome 6 short arm from band p22.2 to band p11.2 (30.2 Mb, 26 987 363–57 190 787 bp) [Figure 4(a)]. The proportion of cells with the three imbalances was evaluated by a previously established formula [8], and the results showed 52–53% abnormal cells, a percentage compatible with the interpretation that these cells shared the three imbalances.

A homozygous deletion of 104.5 kb at band q26.1 of chromosome 3 long arm (162 514 534–162 619 082 bp) was also detected in 100% of cells, and since it is included in the Database of Genomic Variants (DGV; http://projects.tcag.ca/variation/), updated March 2010, it was interpreted as a constitutional benign copy number variation (CNV).

**Patient 2**

The karyotype of BM and PB cells at the onset of t-MDS was 46,XY,der(6)(q16;16)(q21;p21–22) in all 33 metaphases analyzed. This result was confirmed by FISH with wcp and centromeric probes for chromosomes 1 and 6. Definition by a-CGH of the imbalances showed: gain of material of the long arm of chromosome 1 from band q21.1 to qter (103.95 Mb, 145 264 630–249 212 609 bp); loss of chromosome 6 short arm from pter to band p22.2 (26.6 Mb, 170 426–26 663 345 bp); and gain of a segment of chromosome 6 short arm from band p22.2 to band p11.2 (27.3 Mb, 26 971 058–54 310 034 bp) [Figure 4(b)]. The proportion of cells with the three imbalances, evaluated as above, indicated 67–73% of abnormal cells, a percentage compatible with the interpretation that these cells shared the three imbalances.

Another two variations were detected, but present in 100% of cells, and interpreted as a constitutional benign CNV: a heterozygous deletion of 74.9 kb in band q28.2 of chromosome 4 long arm (129 342 168–129 417 126 bp), not included in the DGV mentioned above, and a heterozygous deletion of 56.1 kb in band q22.3 of chromosome 10 long arm (79 743 739–79 799 851 bp), included in the DGV as an inversion variation.

**Discussion**

Complete or partial trisomy of the long arm of chromosome 1 is a recurrent anomaly of pediatric MDS both de novo and therapy-related, in most cases secondary to an unbalanced translocation where the more frequent partner is chromosome 7 [4]. A wide literature survey on cytogenetic abnormalities involving chromosome 1 in myeloid neoplasms has highlighted the chromosomal regions 1q21–32, 1p11–13 and 6p21.3 as potential loci for harboring genes involved in the development and progression of myeloid malignancies [9].

Rearrangements of the short arm of chromosome 6, both balanced and unbalanced, with breakpoints at bands p21–23, have been described in different types of hematological malignancies induced by mutagens in adults. In the majority of cases, this anomaly is present in the context of a complex karyotype, while only in rare cases it has been observed as the sole abnormality [5,10,11]. Although the presence of other chromosomal changes might also suggest that the 6p rearrangement plays a role as a secondary event in development of the neoplastic process, La Starza et al. demonstrated recurrence of the gain of a 5–6 Mb genomic segment at 6p21 in eight cases of t-MDS/t-AML, including a patient with Fanconi anemia. Notably, five out of eight patients with 6p gain had an unbalanced translocation resulting also in 6p terminal deletion. The authors suggest that this kind of 6p rearrangement is a major pathogenetic event arising from acquired and/or congenital genomic instability [7].

Terminal deletion and interstitial duplication of the short arm of chromosome 6 have been reported in an a-CGH study in two adult patients with AML at relapse [12], and an unbalanced karyotype 46,XX,der(6)(1;6)(q12;p22.2), probably with a partial duplication of 6p, was detected by chromosome analysis in two girls with t-MDS following treatment for a primary Ewing/primitive neuroectodermal tumor (PNET) [13,14].

The two patients reported here were affected by t-MDS arising after chemo/radiotherapy for a primary solid tumor. Both cases showed an unbalanced translocation 1/6 resulting

![Figure 4](image-url)

Figure 4. a-CGH profiles of chromosomes 1 and 6 in (a) patient 1 and (b) patient 2, showing gain of material of chromosome 1 long arm, and lost and duplicated regions of chromosome 6 short arm; (c) magnification of the superimposed profiles of both patients (purple, patient 1; light gray, patient 2) at the loss/duplication boundary region of chromosome 6 short arm.
in almost complete trisomy of the long arm of chromosome 1, monosomy of a segment of 26.6 Mb of the short arm of chromosome 6, and an unexpected partial trisomy of 27–30 Mb of the short arm of chromosome 6.

Patient 1 deserves a specific comment because the unbalanced translocation was detected in BM at relapse of the ALCL, 4 years and 6 months before the diagnosis of t-CMML. However, at that time no morphologic evidence of lymphoma cells was present in his BM, notwithstanding the fact that the NPM/ALK rearrangement which characterized the ALCL was still detectable. In the following years, this rearrangement disappeared while the t(1;6) clone persisted: in the analyses performed in 2008 and 2010, BM and PB were NPM/ALK-negative, and all BM mitoses bore the translocation. Evidence is thus sufficient to conclude that the clone with the translocation had no association with the ALCL, and that it eventually led to the t-MDS.

Patient 2 developed MDS and the unbalanced translocation 1/6, 9 years after stopping chemotherapy. Some studies in the literature have reported cases with chromosomal abnormalities including partial trisomy 1q and 6p12–22 rearrangements identified during continuous complete clinical and morphologic remission of AML, and preceding by months the relapse or appearance of MDS features [12,15,16]. Our patients, as well as the two girls with t-MDS mentioned above [13,14], with whom they share the unbalanced karyotype 46,XX,der(6)t(1;6)(q12;p22.2), were treated with polychemotherapy including etoposide and polyclonoside targeting the Philadelphia chromosome in a child with myelodysplastic syndrome following treatment for a primitive neuroectodermal tumor. Leuk Lymphoma 2000;37:213–218.

What is really peculiar in the two cases reported here is the fact that the imbalances due to the translocation were really identical, whereas the partial trisomy was closely similar; only the gained regions differed slightly from each other, but only toward the centromere, being in fact identical at the point at which they began distally [Figure 4(c)]. The duplicated segment of chromosome 6 short arm encompassed both regions suggested as relevant and identified by FISH and by bacterial artificial chromosome (BAC) a-CGH in previous studies concerning adult patients [7,12]. Therefore, at the level of the oligomer-based a-CGH system used, we have described and characterized a new recurrent chromosome change in pediatric t-MDS: an unbalanced translocation 1/6 leading to der(6)(t;1;6)(q21:p22.2)dup(6)(p12.1p22.2), with a cryptic duplication of the short arm of chromosome 6.

We also suggest the possibility of detecting this abnormal clone months/years before the appearance of morphological MDS features.

Potential conflict of interest: Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

References